The role of primary transoral laser microsurgery in laryngeal cancer: a retrospective study
ConclusionIn carefully selected patients with laryngeal cancer, primary TLM with or without adjunctive therapy, can be organ preserving. It can provide a valid treatment option for patients.This article is protected by copyright. All rights reserved.
Publication date: Available online 30 May 2020Source: Pathology - Research and PracticeAuthor(s): Wenjing Qi, Chang Shi, Pengxin Zhang, Lu Feng, Junying Wang, Dan Chen
Publication date: Available online 30 May 2020Source: Gynecologic Oncology ReportsAuthor(s): Anya Laibangyang, Raanan Alter, Yasmin Hasan, S. Diane Yamada
Publication date: Available online 30 May 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Kevin C. Lee, Sung-Kiang Chuang
Publication date: Available online 30 May 2020Source: Pharmacological ResearchAuthor(s): Ling Wang, Ke Deng, Liang Gong, Liang Zhou, Sapna Sayed, Huan Li, Qi Sun, Zijie Su, Zhongyuan Wang, Shanshan Liu, Huifang Zhu, Jiaxing Song, Desheng Lu
CONCLUSION: Repeat transoral laser microsurgery can be an oncologically safe alternative to other salvage therapies for glottic squamous cell carcinoma recurrence, without sacrificing functional outcomes. PMID: 32079549 [PubMed - as supplied by publisher]
In conclusion, overexpression of the CAF-1/p60 protein is related to a risk of higher morbidity and mortality and is a reliable independent prognostic index of laryngeal carcinoma. CAF1-p60 protein overexpression can be used in cancer management as an indicator of malignant evolution, especially in carcinoma in situ. PMID: 28374866 [PubMed - in process]
ConclusionThe patient in this case worked with construction materials including asbestos and supervised construction for 38 years, and was thus exposed to asbestos at construction sites. Much of the asbestos was highly concentrated especially during demolition processes. We therefore consider the laryngeal cancer of this patient to be a work-related disease.
We present a case of huge carcinosarcoma of larynx in a 34 year-old male who developed severe stridor and dysphagia. The diagnosis was confirmed histopathologically, hence the disease was treated through total laryngectomy followed by adjuvant chemotherapy and radiotherapy. The patient is well and hearty for the past one and a half years.
ConclusionHPPH‐PDT can be safely used to treat early‐staged laryngeal cancer, with potential efficacy. © 2015 Wiley Periodicals, Inc. Head Neck, 2015
Conclusions. HPPH‐PDT can be safely used to treat early staged laryngeal cancer, with potential efficacy. This article is protected by copyright. All rights reserved.